A vaccine of L2 epitope repeats fused with a modified IgG1 Fc induced cross-neutralizing antibodies and protective immunity against divergent human papillomavirus types

PLoS ONE

Volumn 9, Issue 5, 2014, Pages

  Chen, Xue ^a   Liu, Hongyang ^a   Zhang, Ting ^a   Liu, Yanchun ^a   Xie, Xixiu ^a   Wang, Zhirong ^a   Xu, Xuemei ^a  

^a INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CAPSID PROTEIN; CAPSID PROTEIN L2; E3R4 PROTEIN; EPITOPE; FC RECEPTOR; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; WART VIRUS VACCINE; DNA VACCINE; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G; L2 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 16; ONCOPROTEIN;

AFFINITY CHROMATOGRAPHY; ALPHAPAPILLOMAVIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; BACULOVIRUS EXPRESSION SYSTEM; CONTROLLED STUDY; FEMALE; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 45; HUMAN PAPILLOMAVIRUS TYPE 5; HUMAN PAPILLOMAVIRUS TYPE 52; HUMAN PAPILLOMAVIRUS TYPE 58; HUMAN PAPILLOMAVIRUS TYPE 6; IMMUNOGENICITY; INFECTION PREVENTION; MOUSE; NONHUMAN; PAPILLOMAVIRUS INFECTION; PROTEIN PURIFICATION; RABBIT; ANIMAL; BAGG ALBINO MOUSE; GENETICS; HUMAN; IMMUNOLOGY;

ANIMALS; ANTIBODIES, NEUTRALIZING; CAPSID PROTEINS; EPITOPES; FEMALE; HUMANS; IMMUNOGLOBULIN FC FRAGMENTS; IMMUNOGLOBULIN G; MICE; MICE, INBRED BALB C; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS VACCINES; RABBITS; VACCINES, DNA;

EID: 84900456204     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0095448     Document Type: Article

References (53)

1. Doorbar J, Quint W, Banks L, Bravo IG, Stoler M, et al. (2012) The biology and life-cycle of human papillomaviruses. Vaccine 30 Suppl 5: F55-70.
2. Gillison ML, Chaturvedi AK, Lowy DR (2008) HPV prophylactic vaccines and the potential prevention of noncervical cancers in both men and women. Cancer 113: 3036-3046.
3. Wheeler CM, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, et al. (2009) The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years. J Infect Dis 199: 936-944.
4. Kemp TJ, Hildesheim A, Safaeian M, Dauner JG, Pan Y, et al. (2011) HPV16/18 L1 VLP vaccine induces cross-neutralizing antibodies that may mediate cross-protection. Vaccine 29: 2011-2014.
5. Alphs HH, Gambhira R, Karanam B, Roberts JN, Jagu S, et al. (2008) Protection against heterologous human papillomavirus challenge by a synthetic lipopeptide vaccine containing a broadly cross-neutralizing epitope of L2. Proc Natl Acad Sci U S A 105: 5850-5855. (Pubitemid 351758461)
6. Gambhira R, Jagu S, Karanam B, Gravitt PE, Culp TD, et al. (2007) Protection of rabbits against challenge with rabbit papillomaviruses by immunization with the N terminus of human papillomavirus type 16 minor capsid antigen L2. J Virol 81: 11585-11592. (Pubitemid 47623790)
7. Xu Y, Wang Q, Han Y, Song G, Xu X (2007) Type-specific and cross-reactive antibodies induced by human papillomavirus 31 L1/L2 virus-like particles. J Med Microbiol 56: 907-913. (Pubitemid 47047482)
8. Day PM, Gambhira R, Roden RB, Lowy DR, Schiller JT (2008) Mechanisms of human papillomavirus type 16 neutralization by l2 cross-neutralizing and l1 type-specific antibodies. J Virol 82: 4638-4646. (Pubitemid 351563700)
9. Richards RM, Lowy DR, Schiller JT, Day PM (2006) Cleavage of the papillomavirus minor capsid protein, L2, at a furin consensus site is necessary for infection. Proc Natl Acad Sci U S A 103: 1522-1527. (Pubitemid 43191198)
10. Rubio I, Bolchi A, Moretto N, Canali E, Gissmann L, et al. (2009) Potent anti-HPV immune responses induced by tandem repeats of the HPV16 L2 (20-38) peptide displayed on bacterial thioredoxin. Vaccine 27: 1949-1956.
11. Rubio I, Seitz H, Canali E, Sehr P, Bolchi A, et al. (2011) The N-terminal region of the human papillomavirus L2 protein contains overlapping binding sites for neutralizing, cross-neutralizing and non-neutralizing antibodies. Virology 409: 348-359.
12. Kondo K, Ishii Y, Ochi H, Matsumoto T, Yoshikawa H, et al. (2007) Neutralization of HPV16, 18, 31, and 58 pseudovirions with antisera induced by immunizing rabbits with synthetic peptides representing segments of the HPV16 minor capsid protein L2 surface region. Virology 358: 266-272. (Pubitemid 46136425)
13. Nakao S, Mori S, Kondo K, Matsumoto K, Yoshikawa H, et al. (2012) Monoclonal antibodies recognizing cross-neutralization epitopes in human papillomavirus 16 minor capsid protein L2. Virology 434: 110-117.
14. Conway MJ, Cruz L, Alam S, Christensen ND, Meyers C (2011) Cross-neutralization potential of native human papillomavirus N-terminal L2 epitopes. PLoS One 6: e16405.
15. Gambhira R, Karanam B, Jagu S, Roberts JN, Buck CB, et al. (2007) A protective and broadly cross-neutralizing epitope of human papillomavirus L2. J Virol 81: 13927-13931. (Pubitemid 350247886)
16. Roden RB, Yutzy WHt, Fallon R, Inglis S, Lowy DR, et al. (2000) Minor capsid protein of human genital papillomaviruses contains subdominant, cross-neutralizing epitopes. Virology 270: 254-257.
17. Phan TG, Grigorova I, Okada T, Cyster JG (2007) Subcapsular encounter and complement-dependent transport of immune complexes by lymph node B cells. Nat Immunol 8: 992-1000. (Pubitemid 47300014)
18. Carrasco YR, Batista FD (2007) B cells acquire particulate antigen in a macrophage-rich area at the boundary between the follicle and the subcapsular sinus of the lymph node. Immunity 27: 160-171. (Pubitemid 47089026)
19. Junt T, Moseman EA, Iannacone M, Massberg S, Lang PA, et al. (2007) Subcapsular sinus macrophages in lymph nodes clear lymph-borne viruses and present them to antiviral B cells. Nature 450: 110-114. (Pubitemid 350070574)
20. Szakal AK, Holmes KL, Tew JG (1983) Transport of immune complexes from the subcapsular sinus to lymph node follicles on the surface of nonphagocytic cells, including cells with dendritic morphology. J Immunol 131: 1714-1727. (Pubitemid 13010141)
21. Carrasco YR, Batista FD (2006) B cell recognition of membrane-bound antigen: an exquisite way of sensing ligands. Curr Opin Immunol 18: 286-291. (Pubitemid 44304340)
22. Steinman RM, Banchereau J (2007) Taking dendritic cells into medicine. Nature 449: 419-426. (Pubitemid 47509552)
23. Slupetzky K, Gambhira R, Culp TD, Shafti-Keramat S, Schellenbacher C, et al. (2007) A papillomavirus-like particle (VLP) vaccine displaying HPV16 L2 epitopes induces cross-neutralizing antibodies to HPV11. Vaccine 25: 2001-2010. (Pubitemid 46227679)
24. Schellenbacher C, Roden R, Kirnbauer R (2009) Chimeric L1-L2 virus-like particles as potential broad-spectrum human papillomavirus vaccines. J Virol 83: 10085-10095.
25. Schellenbacher C, Kwak K, Fink D, Shafti-Keramat S, Huber B, et al. (2013) Efficacy of RG1-VLP Vaccination against Infections with Genital and Cutaneous Human Papillomaviruses. J Invest Dermatol 133: 2706-2713.
26. Tumban E, Peabody J, Tyler M, Peabody DS, Chackerian B (2012) VLPs displaying a single L2 epitope induce broadly cross-neutralizing antibodies against human papillomavirus. PLoS One 7: e49751.
27. Tumban E, Peabody J, Peabody DS, Chackerian B (2013) A universal virus-like particle-based vaccine for human papillomavirus: longevity of protection and role of endogenous and exogenous adjuvants. Vaccine 31: 4647-4654.
28. Nieto K, Weghofer M, Sehr P, Ritter M, Sedlmeier S, et al. (2012) Development of AAVLP(HPV16/31L2) particles as broadly protective HPV vaccine candidate. PLoS One 7: e39741.
29. Qi Z, Pan C, Lu H, Shui Y, Li L, et al. (2010) A recombinant mimetics of the HIV-1 gp41 prehairpin fusion intermediate fused with human IgG Fc fragment elicits neutralizing antibody response in the vaccinated mice. Biochem Biophys Res Commun 398: 506-512.
30. Zaharatos GJ, Yu J, Pace C, Song Y, Vasan S, et al. (2011) HIV-1 and influenza antigens synthetically linked to IgG2a Fc elicit superior humoral responses compared to unmodified antigens in mice. Vaccine 30: 42-50.
31. Ye L, Zeng R, Bai Y, Roopenian DC, Zhu X (2011) Efficient mucosal vaccination mediated by the neonatal Fc receptor. Nat Biotechnol 29: 158-163.
32. Du L, Leung VH, Zhang X, Zhou J, Chen M, et al. (2011) A recombinant vaccine of H5N1 HA1 fused with foldon and human IgG Fc induced complete cross-clade protection against divergent H5N1 viruses. PLoS One 6: e16555.
33. Konduru K, Bradfute SB, Jacques J, Manangeeswaran M, Nakamura S, et al. (2011) Ebola virus glycoprotein Fc fusion protein confers protection against lethal challenge in vaccinated mice. Vaccine 29: 2968-2977.
34. Jensen MA, Arnason BG, White DM (2007) A novel Fc gamma receptor ligand augments humoral responses by targeting antigen to Fc gamma receptors. Eur J Immunol 37: 1139-1148. (Pubitemid 46925349)
35. White DM, Pellett S, Jensen MA, Tepp WH, Johnson EA, et al. (2011) Rapid immune responses to a botulinum neurotoxin Hc subunit vaccine through in vivo targeting to antigen-presenting cells. Infect Immun 79: 3388-3396.
36. Duncan AR, Woof JM, Partridge LJ, Burton DR, Winter G (1988) Localization of the binding site for the human high-affinity Fc receptor on IgG. Nature 332: 563-564.
37. Lund J, Winter G, Jones PT, Pound JD, Tanaka T, et al. (1991) Human Fc gamma RI and Fc gamma RII interact with distinct but overlapping sites on human IgG. J Immunol 147: 2657-2662.
38. Zhang T, Xu Y, Qiao L, Wang Y, Wu X, et al. (2010) Trivalent Human Papillomavirus (HPV) VLP vaccine covering HPV type 58 can elicit high level of humoral immunity but also induce immune interference among component types. Vaccine 28: 3479-3487.
39. Xie X, Liu Y, Zhang T, Xu Y, Bao Q, et al. (2013) Human papillomavirus type 58 L1 virus-like particles purified by two-step chromatography elicit high levels of long-lasting neutralizing antibodies. Arch Virol 158: 193-199.
40. Buck CB, Pastrana DV, Lowy DR, Schiller JT (2004) Efficient intracellular assembly of papillomaviral vectors. J Virol 78: 751-757. (Pubitemid 38067597)
41. Buck CB, Pastrana DV, Lowy DR, Schiller JT (2005) Generation of HPV pseudovirions using transfection and their use in neutralization assays. Methods Mol Med 119: 445-462.
42. Jagu S, Kwak K, Karanam B, Huh WK, Damotharan V, et al. (2013) Optimization of multimeric human papillomavirus L2 vaccines. PLoS One 8: e55538.
43. Jagu S, Karanam B, Gambhira R, Chivukula SV, Chaganti RJ, et al. (2009) Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines. J Natl Cancer Inst 101: 782-792.
44. Castanon S, Marin MS, Martin-Alonso JM, Boga JA, Casais R, et al. (1999) Immunization with potato plants expressing VP60 protein protects against rabbit hemorrhagic disease virus. J Virol 73: 4452-4455. (Pubitemid 29189894)
45. Embers ME, Budgeon LR, Culp TD, Reed CA, Pickel MD, et al. (2004) Differential antibody responses to a distinct region of human papillomavirus minor capsid proteins. Vaccine 22: 670-680. (Pubitemid 38114897)
46. He Y, Zhou Y, Liu S, Kou Z, Li W, et al. (2004) Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: implication for developing subunit vaccine. Biochem Biophys Res Commun 324: 773-781. (Pubitemid 39345582)
47. Martyn JC, Cardin AJ, Wines BD, Cendron A, Li S, et al. (2009) Surface display of IgG Fc on baculovirus vectors enhances binding to antigen-presenting cells and cell lines expressing Fc receptors. Arch Virol 154: 1129-1138.
48. Zhang MY, Wang Y, Mankowski MK, Ptak RG, Dimitrov DS (2009) Cross-reactive HIV-1-neutralizing activity of serum IgG from a rabbit immunized with gp41 fused to IgG1 Fc: possible role of the prolonged half-life of the immunogen. Vaccine 27: 857-863.
49. Fusco WG, Afonina G, Nepluev I, Cholon DM, Choudhary N, et al. (2010) Immunization with the Haemophilus ducreyi hemoglobin receptor HgbA with adjuvant monophosphoryl lipid A protects swine from a homologous but not a heterologous challenge. Infect Immun 78: 3763-3772.
50. Leenaars PPAM, Hendriksen CFM, Angulo AF, Koedam MA, Claassen E (1994) Evaluation of Several Adjuvants as Alternatives to the Use of Freunds-Adjuvant in Rabbits. Veterinary Immunology and Immunopathology 40: 225-241. (Pubitemid 24066510)
51. Mallon FM, Graichen ME, Conway BR, Landi MS, Hughes HC (1991) Comparison of Antibody-Response by Use of Synthetic Adjuvant System and Freund Complete Adjuvant in Rabbits. American Journal of Veterinary Research 52: 1503-1506.
52. Jennings GT, Bachmann MF (2008) The coming of age of virus-like particle vaccines. Biol Chem 389: 521-536. (Pubitemid 351874198)
53. Schiller JT, Lowy DR (2012) Understanding and learning from the success of prophylactic human papillomavirus vaccines. Nature Reviews Microbiology 10: 681-692.